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Gene dosage effects
of poly(A) track-engineered hypomorphs
Geralle Powell,1 Slavica Pavlovic Djuranovic,1 and Sergej Djuranovic1
1Department

of Cell Biology and Physiology, Washington University School of Medicine, 600 South Euclid Avenue, Campus Box 8228, St. Louis, MO 63110, USA

Manipulation of gene activity through creation of hypomorphic mutants has been a long-standing tool in examining
gene function. Our previous studies have indicated that hypomorphic mutants could be created by inserting cis-regulatory
sequences composed of consecutive adenosine nucleotides
called poly(A) tracks. Here we use poly(A) tracks to create
hypomorphic mutants and functional characterization of
membrane, secretory, and endogenous proteins. Insertion of
poly(A) tracks into the sequences of interleukin-2 and membrane protein CD20 results in a programmable reduction of
mRNA stability and attenuation of protein expression regardless of the presence of a signaling sequence. Likewise, CRISPRCas9 targeted insertion of poly(A) tracks into the coding
sequence of the endogenous human genes AUF1 and TP53 results in a programmable reduction of targeted protein and
mRNA levels. Functional analyses of AUF1-engineered hypomorphs indicate a direct correlation between AUF1 gene levels
and the stability of AUF1-regulated mRNAs. Hypomorphs of
TP53 affect expression of the target genes differentially depending on the severity of the hypomorphic mutation. Finally,
decreases in TP53 protein affect the same cellular pathways in
poly(A) track-engineered cells as in cancer cells, indicating
these variants’ biological relevance. These results highlight
this technology’s power to create predictable, stable hypomorphs in recombinant or endogenous genes in combination
with CRISPR-Cas9 engineering tools.

INTRODUCTION
Investigation of a gene’s phenotype and its functional importance has
often occurred by creating loss-of-function (LOF) mutations. LOF
mutations allow examination of phenotype when gene expression is
reduced (as with hypomorphic mutations) or completely ablated
(as with “null” mutations).1 However, phenotypic investigation of
LOF mutations can be troublesome because of embryonic lethality
or disruption of organismal development as a result of pleiotropy.2,3
Therefore, use of hypomorphic mutations is often preferable and
more experimentally advantageous.
There are several methods for creating hypomorphic mutations. Historically, chemical and UV irradiation mutagenesis screens followed
by selection for phenotypic strength have been used to identify hypomorphic alleles.1,4-6 Hypomorphic mutations have also been created
through non-directed insertional mutagenesis using transposable el-

ements in or near regulatory regions.7,8 RNAi has also been an essential tool in creating hypomorphic phenotypes because of varying degrees of residual gene expression produced from knockdown.9-11
However, each method of creation of hypomorphic mutations is
accompanied by disadvantages. Although advances in next-generation sequencing have reduced the time and tediousness associated
with ﬁnding phenotypic variants in traditional forward genetics
screens, the process still requires creating a mapping population,
with mapping resolution being variable.12-14 Even when an allele is
mapped to a gene of interest, mutagenesis screens still produce
many other types of alleles, such as neomorphs (altered or unique
function), nulls (LOF), and hypermorphs (gain of function). On the
other hand, RNAi results in variable gene knockdown and can have
off-target effects.15 Therefore, there is a need for a method that can
be used for all recombinant coding genes and, in combination with
novel CRISPR-Cas9 technologies, to engineer endogenous genes.
We have previously described poly(A) tracks as stretches of adenosine
nucleotides that decrease mRNA stability during the elongation phase
of mRNA translation, causing ribosomal stalling and frameshifting.16
The direct consequence of these events is a decrease in protein expression and mRNA stability.16-20 The decrease in the amount of gene
expression directly correlates with the length of the poly(A) track:
the longer the poly(A) track, the lower the mRNA’s stability and
expression of the protein products.16,17,19,20 Our previous work indicated that poly(A) tracks could be used to create hypomorphic levels
of recombinant cytoplasmic proteins in various reporters and across
multiple organisms, such as E.coli, S. cerevisiae, T. thermophile, and
N. benthamiana and in Drosophila and human cells.19 Additional
studies have indicated that the same technology can be used in
C. albicans and A. thaliana cells, where constructs with poly(A) tracks
were inserted into previously engineered knockout cells.20
Previous studies of poly(A) track hypomorphs have been limited to
reporters or recombinant cytoplasmic proteins and were not tested
in secretory or membrane proteins.19 Because the sequence and structure of the N terminus of secretory and transmembrane proteins are
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essential for co-translational translocation and, thus, proper processing and transport, it remains unclear whether insertion of poly(A)
tracks would create hypomorphic mutants of such genes.21-23 Moreover, it is still unknown whether poly(A) tracks could be engineered
in endogenous genes by using the CRISPR-Cas9 system.
In this work, we show how insertion of poly(A) tracks into genes for
integral membrane-spanning 4A1 (referred to hereafter as CD20)
and secretory IL-2 (interleukin-2) regulates their recombinant protein
expression. Inserting a poly(A) track of at least 9 and up to 18 adenosines reduces mRNA stability and protein synthesis in a programmable
way without affecting protein membrane insertion or secretion out of
the cells. This effect is also independent of the presence of the signaling
peptide sequence in IL-2, where insertion of a poly(A) track immediately before and after the signal sequence results in a similar protein
and mRNA reduction. We show that the same effects can be observed
when poly(A) track sequences are introduced into endogenous genes in
human tissue cultures using CRISPR-Cas9 technology. AUF1(AU-rich
element RNA-binding protein 1) and TP53 (tumor protein p53)
mRNA stability and protein expression are reduced in a programmable
way, depending on the length of poly(A) tracks. Analyses of downstream effects of AUF1 hypomorphs indicate changes in the abundance
of MAT1A (methionine adenosyltransferase 1A), APP (b-amyloid precursor protein), TOP2A (DNA topoisomerase II alpha), and USP1
(ubiquitin-speciﬁc peptidase 1) mRNAs, shown previously to respond
to AUF1 protein.24,25 Inserting poly(A) tracks in the TP53 locus of
HAP1 cells leads to partial or near-complete loss of TP53 protein
and TP53 dosage-dependent effects on multiple TP53-regulated genes.
Our data also indicate that partial or more complete loss of TP53 gene
expression leads to downregulation of MGMT (O-6-methylguanineDNA methyltransferase) gene products, a trend observed in engineered
cells and cancer cell lines with compromised levels of TP53 protein.
Overall, the poly(A) track method successfully creates hypomorphic
mutations in secretory and membrane proteins as well as in endogenous genes. We also show successful application of this method in
haploid and diploid genomes. Finally, creation of hypomorphic mutants using CRISPR-Cas9 in conjunction with poly(A) track sequence
insertion allows controlled investigation of downstream genes and
pathways. This method provides titratable gene expression in a
feasible and experimentally tractable way.

RESULTS
Insertion of poly(A) tracks creates hypomorphic mutants of the
membrane gene CD20

To investigate whether poly(A) track technology can be used for membrane proteins, we focused on CD20.26 CD20 is a B lymphocyte-speciﬁc integral membrane protein essential for differentiation of these
cells.27 As a member of the membrane-spanning 4A gene family encoded by the MS4A1 gene, CD20 is a 33- to 37-kDa protein with
four hydrophobic transmembrane helices, one intracellular loop, and
two extracellular loops with cytosolic N and C termini, respectively.28
Because CD20 lacks an N-terminal signal peptide, its correct expression
and translocation depend on its ﬁrst transmembrane domain.27-29
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To test whether insertion of poly(A) tracks can lead to programmable
expression of CD20, we cloned the full sequence of CD20 into the
pDEST40 vector and inserted poly(A) tracks of 12 adenosines
(12As, sequence equivalent to 4 consecutive lysine AAA codons)
and 18As (sequence equivalent to 6 lysine AAA codons), respectively,
after the second amino acid (Figure 1A). We transfected wild-type
(WT) and mutated CD20 reporters together with a Green Fluorescence Protein - Yellow Fluorescence Protein (GFP-YFP) reporter as
a normalization control into Chinese hamster ovary (CHO) cells. Using qRT-PCR and western blot analysis, we examined the effects of
poly(A) insertion on CD20 mRNA stability and protein expression
(Figures 1B and 1C). The recombinant CD20 protein was visualized
using a polyclonal CD20 antibody and compared with expression
of GFP-YFP constructs. Expression of the CD20 protein was
decreased over approximately 50% and 80% for reporters with insertion of 12As and 18As, respectively (Figure 1B), with previously
observed degradation bands at 25 kDa.29 We observed similar,
approximately 50% and 70% reductions in mRNA stability for constructs with insertion of 12As and 18As, respectively (Figure 1C).
To investigate whether insertion of poly(A) tracks and expression of
CD20 protein with short poly-lysine repeats interferes with cellular
localization of this membrane-integral protein, we used live-cell imaging (Figure 2A) and ﬂow cytometry analysis (Figure 2B). Using a
ﬂuorescein isothiocyanate (FITC)-labeled CD20-2H7-speciﬁc antibody, we performed live-cell imaging of CHO cells expressing WT
CD20 and poly(A) track variants. The monoclonal CD20 antibody
2H7 binds an epitope found in the larger extracellular loop of
CD20 and has been used for depletion of B cells.30,31 Antibody immunoﬂuorescence indicated that all three variants of CD20 are expressed
in the membrane of CHO cells.32 Furthermore, the position of the
FITC-labeled CD20-2H7-speciﬁc antibody indicated a distribution
of CD20 similar to the CellMask Orange plasma membrane stain
(Figure 2A; Figure S1). The difference in the levels of cellular immunoﬂuorescence was similar to the difference in protein levels seen in
western blot analyses (Figure 1B). Cells expressing the WT CD20
construct had the highest immunoﬂuorescence signal, whereas
poly(A) track-engineered constructs had a programmable reduction
in the abundance of the CD20 protein. CD20 protein with insertion
of a poly(A) track of 12As had higher immunoﬂuorescence than
CD20 with 18As. Flow cytometry of transfected CHO cells with a
FITC-labeled CD20-antibody also indicated detectable levels of
expression of WT CD20 and CD20 with a poly(A) track of 12As
(Figure 2B).33
Insertion of a poly(A) tracks creates hypomorphic mutants of
secretory IL-2 protein regardless of signaling peptide

To test the ability to create hypomorphic mutants using poly(A)
tracks in secretory proteins, we created reporter genes with the fulllength sequence of IL-2. IL-2 is a cytokine necessary for homeostasis
of T lymphocytes and clonal expansion of regulatory T cells.34,35 As a
secretory protein, IL-2 contains an N-terminal signal peptide for
recognition by the signal recognition particle and efﬁcient co-translational translocation. It has been shown previously that modiﬁcation
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Figure 1. Design and effect of poly(A) track insertion
on CD20 stability and expression
(A) Scheme representative of poly(A) insertions and location of insertions for CD20 reporter constructs used in this
study. Poly(A) insertions in the CD20 coding sequence
were placed proximal to the ATG start codon. A schematic
of the CD20 gene with the start codon (ATG), termination
codon (STOP), and exons and insertion sites is also
shown. (B) Western blot analysis of CD20 constructs expressed transiently in CHO cells. An equal amount of total
protein was used for analysis. GFP-YFP and b-actin were
used as transfection and loading controls, respectively,
with expression of both proteins detected using specific
antibodies. CD20 was detected with a CD20-specfic
antibody. Arrows indicate the position of full-length CD20,
GFP-YFP, and b-actin proteins. (C) mRNA levels of CD20
constructs were measured by qRT-PCR. CD20 expression was normalized to b-actin. Relative mRNA levels for
both constructs (12As and 18As) are presented as percentages of WT CD20. Error bars represent mean ± SD
(n = 3). p values represent significance (*p % 0.05, **p %
0.01, ***p % 0.001, ****p % 0.0001).

C

of the signal peptide of IL-2 could affect IL-2 expression and
secretion.36
To test the locational ﬂexibility of poly(A) insertion, we placed
poly(A) tracks of 9As, 12As, and 18As, respectively, before and after
the signal peptide sequence (Figure 3A). Poly(A) tracks before the
signal peptide were inserted after the codon for the second amino
acid, whereas insertion after the signal peptide sequence occurred
following the codon for amino acid 27. We transfected WT IL-2
and IL-2 reporters with poly(A) track insertions into human embryonic kidney 293 (HEK293) cells. These cells have been shown previously to produce secreted IL-2 protein when transfected with recombinant IL-2.37,38 We assayed mRNA amounts by qRT-PCR analysis
for all reporters. RNA levels were reduced by approximately 20%,
40%, and 50% for 9As, 12As, and 18As, respectively, for poly(A)

tracks inserted before the signal sequence and
30%, 50%, and 70% for poly(A) tracks inserted
after the signal sequence, respectively (Figure 3B). We used cell medium to measure the
amount of secreted IL-2 protein 48 h after transfection and applied it to a standardized IL-2
sandwich ELISA (Thermo Fisher Scientiﬁc,
EH2IL2). To check the linearity of the IL-2
ELISA, we diluted WT IL-2 samples from 2and up to 16-fold and used medium from untransfected cells as a control (WT NI - wild
type no insert construct). Similar to the
mRNA experiments, protein expression was
reduced in IL-2 variants with poly(A) tracks
regardless of position respective to the signal
peptide sequence (Figure 3C). Insertion of
9As, 12As, or 18As consistently led to 60%–70%, 80%, or more
than 90% reduction in IL-2 levels, as detected by ELISA (Figure 3C),
regardless of whether insertion of the poly(A) track was before or after
the signal peptide.
Finally, to test the functionality of the IL-2 variants with poly(A)
tracks, we used an IL-2 cell-based assay (IL2 Bioassay, Promega),
which reports stimulation of the IL-2 receptor through expression
of the luciferase reporter (Figure 3D). Results for supernatants of
the WT IL-2 sample or IL-2 variants with poly(A) tracks indicated
functionally active proteins, regardless of the position of poly(A) track
to encoded signaling peptide. Moreover, the luminescence levels from
the functional IL-2 assay indicated a change in the levels of IL-2 protein and poly(A) track hypomorphs similar to what we observed previously in ELISA assays (Figure 3B).
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Figure 2. CD20 hypomorph live imaging and flow
cytometry
(A) Fluorescence and bright-field (BF) microscopy images
of live CHO cells expressing the CD20, CD20 12As, and
CD18As constructs. CD20-positive cells were labeled
using an anti-CD20-2H7 FITC-labeled antibody. The cell
membrane is labeled with CellMask Orange stain. Control
non-transfected CHO cells are indicated. DNA was
labeled with Hoechst 33342 stain. The scale bar represents 10 mm. (B) Representative graphs showing flow
cytometry scatterplots of CHO cells expressing CD20 and
CD20 12As co-transfected with the mCherry construct.
CHO cells expressing only mCherry and non-transfected
cells are used as controls. The cells were stained an with
anti-CD20-2H7 FITC-labeled antibody.

A

whether endogenous hypomorphic mutants
could be created using CRISPR-Cas9 technology
to insert poly(A) tracks of various lengths into
endogenous gene loci in human tissue cultures.
Using this method, we created endogenous
hypomorphic mutants in the TP53 (tumor protein 53) gene and AUF1 in HAP1 and HEK293
cells, respectively (Figures 4 and 5).
Guide RNAs (gRNAs) were designed to facilitate Cas9 nuclease activity in the fourth exon
of the TP53 gene (Figure S2). This gene locus encodes the loop region in the TP53 protein. We
selected this position to assure targeting of the
two major N-terminal isoforms of TP53 transcripts: canonical TP53, which contains the
full N-terminal sequence, and D40TP53, which
excludes the ﬁrst 40 amino acids of the canonical TP53 isoform because of the presence of an
internal start (AUG) codon (Figure 4A; Figure S2).40 gRNAs were chosen for high NHEJ
(non-homologous end joining) efﬁciency, low
off-target effects, and proximity to the cut site.
ssODN (single-strand oligo donor) DNA containing homology arms ﬂanking the 30 and 50 regions of the poly(A) track insertion sequence
(12As or 36As) was used as a template for
CRISPR-mediated HDR (homology-directed
repair) in the human near-haploid cell line
HAP1.41

B

CRISPR-Cas9 insertion of poly(A) tracks in the TP53
endogenous locus in the near-haploid HAP1 cell line

With CRISPR-Cas9 technology development, a range of gene modiﬁcations, including point mutations, insertions, and deletions, can
be made at precise genomic locations.39 We wanted to ﬁnd out
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After CRISPR-Cas9 engineering of the TP53 locus, we selected and conﬁrmed by NGS (nextgeneration sequencing) and Sanger sequencing multiple cell clones
containing an insertion of 12As or 36As (Figure S2). Engineered
cell lines with successful insertion of poly(A) tracks in the single
copy of the TP53 gene in HAP1 cells were analyzed for mRNA stability and protein expression of the TP53 gene using qPCR and western
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blot analysis. GAPDH protein and mRNA levels were used as normalization controls between parental and engineered cell lines. Similar to
the CD20 and IL-2 reporters, endogenous TP53 hypomorphs containing 12As or 36As had decreased mRNA levels and protein abundance, depending on the length of the inserted poly(A) track (Figures
4B and 4C). The 12A insertion reduced mRNA and protein amounts
by 50% compared with WT TP53 expression in the original HAP1
parental line. Insertion of 36As resulted in almost complete loss of
the TP53 protein and a 90% reduction in mRNA levels compared
with TP53 levels in the original non-engineered HAP1 cells.
poly(A) tracks engineered in AUF1 endogenous loci of diploid
HEK293 cells result in programmable hypomorphs

C

To test whether a CRISPR-Cas9 approach can be used to create
poly(A) track hypomorphs in a human-derived diploid cell line, we
targeted the AUF1 gene loci in the HEK293 T-Rex cell line (Invitrogen). As with the TP53 gene, we introduced poly(A) tracks of 12As or
18As in the open reading frame of AUF1 (Figure 5; Figure S3). This
time we engineered poly(A) tracks in the ﬁrst exon of the AUF1 gene
after the second amino acid to assure targeting of all potential isoforms of AUF1 protein (Figure 5A).42 After isolation of cell clones
and conﬁrmation of the poly(A) track insertion (Figure S3), cell lysates were analyzed for AUF1 mRNA levels and protein expression
(Figures 5B and 5C). Similar to TP53, the mRNA stability and protein
expression of endogenously engineered AUF1 hypomorphs were
decreased in a length-dependent manner. Insertion of the poly(A)
track of 12As led to a 50% and 40% reduction in protein and
mRNA levels of AUF1, respectively. Insertion of 18As further reduced
protein levels to approximately 10% of the parental cell line levels,
whereas mRNA levels were reduced by 60%.
Hypomorphs of AUF1 affect mRNA levels of downstream target
mRNAs

D

Figure 3. Effects of poly(A) insertions on IL-2 reporter expression, stability,
and activity
(A) Scheme representative of poly(A) insertions and location of insertions for IL-2
reporter genes used in this study. Poly(A) insertions were placed before and after the
signaling sequence (SS). IL-2 constructs containing the full-length WT IL-2
sequence and insertions of 9As, 12As, and 18As, respectively, were transiently
expressed in HEK293 cells. Also shown is a schematic of the IL-2 gene with the start
codon (ATG), termination codon (STOP), SS, exons, and insertion sites. (B) ELISA
measured levels of IL-2 protein expression. IL-2 protein levels are calculated from

To test whether created hypomorphs with poly(A) insertions endogenously could be used to study the function of the gene with regard to
established downstream targets, we performed expression analysis on
TP53 and AUF1 hypomorphs (Figures 5D and 6). We measured the
steady-state levels of the MAT1A, APP, TOP2A, and USP1 mRNAs
in the parental HEK293 T-Rex cell line and the lines with engineered
AUF1 hypomorphs (Figure 5D). MAT1A mRNA was previously stabilized by knockdown of AUF1, whereas transient knockdown of
cell supernatant collected from control (WT NI) HEK293 cells and cells expressing
WT IL-2 and IL-2 with poly(A) tracks (9As, 12As, and 18As). A standard curve was
used to obtain mean net absorbance. Dilutions of the supernatants from WT IL-2
(1:2–1:16) indicate linearity of the assay. (C) mRNA levels of IL-2 constructs were
measured by qRT-PCR. IL-2 expression was normalized to b-actin. Relative mRNA
and protein levels for control (), WT IL-2, and IL-2 poly(A) track constructs (9As,
12As, and 18As) are presented as percentages of WT IL-2. (D) Biological activity of
IL-2 was measured by the IL-2 bioassay (Promega). Relative IL-2 activity is
measured by luciferase expression and normalized to supernatant of the WT IL-2
construct. Control (WT NI) and IL-2 poly(A) track constructs (9As, 12As, and 18As)
are presented as percentages of WT IL-2. Error bars represent mean ± SD (n = 3). p
values represent significance (*p % 0.05, **p % 0.01, ***p % 0.001, ****p %
0.0001).
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Figure 4. Creation and expression levels of endogenous TP53 poly(A) track hypomorphs in HAP1 cells using CRISPR-Cas9 genomic editing
(A) Cartoon representing the design of CRISPR-Cas9-mediated insertion of poly(A) tracks in the DNA sequence of TP53. The blue dashed line indicates the Cas9 (scissors)
cleavage site and location of poly(A) track insertion (12As or 36As). The canonical and N-terminally truncated (delta 40) isoforms are shown with the engineered poly(A) tracks
(blue). (B) Western blot analysis of WT HAP1 cells and HAP1 cells with endogenous poly(A) track insertions of 12As and 36As, respectively. Equal protein was used for
analysis. TP53 was detected using a TP53-specific antibody. Constitutively expressed GAPDH was used as a loading control and was detected using a specific antibody. (C)
The mRNA level of TP53 in WT HAP1 and TP53 hypomorphs was detected by qRT-PCR. TP53 expression was normalized to GAPDH mRNA expression. Relative mRNAs
levels are presented as a percentage of WT TP53. Error bars represent mean ± SD (n = 3). p values represent significance (*p % 0.05, **p % 0.01, ***p % 0.001, ****p %
0.0001). Arrows indicate the positions of the full-length proteins.

AUF1 by small interfering RNA (siRNA) transfection induces destabilization of APP, TOP2A, and USP1 mRNAs.34 Our results conﬁrm
the observations of previous studies.24,25 MAT1A mRNA levels increase in the programmed hypomorphs of AUF1, whereas the levels
of APP, TOP2A, and USP1 decline with a reduction in AUF1 expression. Even more compelling, the change in target gene mRNA levels
was dependent on the length of the poly(A) track insertion and the
extent of AUF1 reduction. Insertion of 18As has a more pronounced
effect on mRNA stability than 12As (Figure 5D).
Hypomorphs of TP53 affect downstream genes in a dosedependent manner

To extend our studies to potential use of programmable hypomorphs
for gene dosage effects, we analyzed how insertion of poly(A) tracks in
the TP53 gene and reduction of TP53 gene products affects downstream pathways known to be controlled or connected to TP53 protein. Based on previous studies and availability of antibodies, we
selected BRCA1, DDIT4, DUSP6, MGMT, and P21 as TP53-associated genes.43-49 We analyzed cell lysates by qPCR and western blot
analysis (Figures 6A and 6B). We used parental HAP1 cells and engi-
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neered HAP1 cells with 12A and 36A insertions in the TP53 coding
sequence (Figure 3). Tp53 protein and mRNA levels in these cells reﬂected WT TP53 levels, a 50% reduction in TP53 (TP53 12As), and
nearly complete loss of TP53 protein (TP53 36As) (Figures 4B and
4C, 6A, and 6B). Western blot analyses indicated that BRCA1 levels
did not change regardless of TP53 protein levels (Figure 6A). The protein levels of DUSP6 and DDIT4 showed differential behavior in the
presence of the varying TP53 levels (Figure 6A). A 50% reduction of
TP53 protein levels caused by insertion of a poly(A) track with 12As
led to a signiﬁcant reduction of DDIT4 and almost complete loss of
DUSP6 protein in those cells (HAP1 TP53 12As). DDIT4 and
DUSP6 were not affected or slightly increased in cells with almost
complete loss of TP53 (HAP1 TP53 36As) compared with WT
HAP1 cells. Finally, MGMT and P21 protein levels were severely
depleted in cells expressing TP53 hypomorphs compared with WT
HAP1 cells. Analyses of steady-state mRNA levels for all genes indicated the same trend as protein levels (Figure 6B). BRCA1 mRNA
levels were unaffected in cell lines with different TP53 levels.
DDIT4 and DUSP6 mRNAs showed a signiﬁcant drop in levels,
with a 50% TP53 protein reduction and WT or higher levels of
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Figure 5. Design and gene-regulatory effect of endogenous AUF1 poly(A) track hypomorphs created using CRISPR-Cas9 genome engineering in HEK293
cells
(A) Cartoon representing the location of poly(A) track insertion in the DNA coding region of AUF1. The dashed blue line represents the Cas9 (scissors) cut site and location of
poly(A) insertion (12As or 18As). Four of the major AUF1 mRNA isoforms (p45, p42, p40, and p37) are shown with their respective poly(A) insertions. (B) Western blot analysis
of WT HEK293 cells and HEK293 cells with endogenous poly(A) insertions of 12As and 18As, respectively. Equal protein was used for analysis. AUF1 was detected with a
specific antibody. Constitutively expressed HSP70 was used as a loading control and was detected using a specific antibody. (C) The mRNA level of AUF1 in WT HEK293
cells and AUF1 hypomorphs was detected by qRT-PCR. GAPDH was used for normalization of total mRNA levels. Relative mRNA levels are presented as a percentage of WT
AUF1 as expressed in WT HEK293 cells. (D) The mRNA levels of the AUF1 downstream targets MAT1A, APP, TOP2A, and USP1 were detected by qRT-PCR. GAPDH was
used to normalize total mRNA levels. Error bars represent mean ± SD (n = 3). p values represent significance (*p % 0.05, **p % 0.01, ***p % 0.001, ****p % 0.0001). Arrows
indicate the positions of the full-length proteins.

mRNAs in cells with almost complete loss of TP53. Finally, MGMT
and P21 mRNA levels were severely depleted in both TP53 engineered cell lines. We further tested whether TP53 and P21 levels
can be changed when we apply hydroxyurea to HAP1 cells as a cytotoxic and genotoxic drug (Figure 6C).50 We observed moderate increase in WT TP53 levels after 3- and 24-h treatment. Levels of
TP53 with a 12A poly(A) track only changed after 24 h, and we did
not observe detectable levels of TP53 with 36A insertion even after
24 h of hydroxyurea treatment. The P21 levels in the WT sample
were induced after 3 h of hydroxyurea treatment and reduced after
24 h. Cells with 12A TP53 hypomorphic variants showed delayed induction of P21 levels only after 24-h hydroxyurea treatment, whereas
cells with the 36A TP53 variant failed to show any induction of P21
even 24 h after hydroxyurea treatment (Figure 6C).

cells from individuals with cancer, we obtained four TP53 mutant or
deletion cell lines (Figure 6D) and focused on MGMT protein levels.
Based on our hypomorphic models, we predicted that cell lines that
contain less TP53 would contain less MGMT. In cell lines with WT
TP53 status (HEK293 and MIA PaCa-2), MGMT protein expression
was easily detectible. The SW620 cell line has a double mutation in
the TP53 gene (R273H/P309S) and deletion of the MGMT gene. As expected, TP53 protein levels were greatly reduced in the SW620 cell line,
and MGMT protein expression was not observed. In the two cell lines
that have negligible amounts of TP53 protein, PA14C (del - deletion of
TP53) and K562 (Q136fs), MGMT protein levels were completely
depleted (Figure 6D). These data indicate that our hypomorphic
TP53 model can predict levels of the downstream gene MGMT.

DISCUSSION
Finally, to test whether the poly(A) track hypomorphs can reproduce
some of the results of gene mutations or deletions found in established

In this study, we present a comprehensive method of creating hypomorphic mutations through insertion of poly(A) tracks. Using these
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Figure 6. Effects of hypomorphic TP53 expression on the gene dosage of downstream targets
(A) Western blot analysis of BRCA1, DDIT4, DUSP6, MGMT, P21, and TP53 protein levels in WT and TP53 poly(A) track (12As and 36As) HAP1 engineered cells. Equal
amounts of total protein were used for analysis. BRCA1, DDIT4, DUSP6, MGMT, P21, and TP53 expression was identified using a specific antibody. GAPDH and ACTIN were
used as loading controls in each blot and were detected using specific antibodies. (B) BRCA1, DDIT4, DUSP6, MGMT, P21, and TP53 mRNA levels in WT and TP53 poly(A)
track (12As and 36As) engineered cells. Relative mRNAs levels are presented as a percentage of the mRNA levels of the WT gene as expressed in WT HAP1 cells. (C) Western
blot analyses of TP53 and P21 proteins in hydroxyurea-treated and control (NT - non treated) cells. The length of hydroxyurea treatment is indicated for WT and TP53 poly(A)
track (12As and 36As) engineered cells. (D) Western blot analysis of TP53 and MGMT expression in HEK293, MIA PaCa2, SW620, Pa14C, and K562 cells. ACTIN was used
to normalize total protein levels. Error bars represent mean ± SD (n = 3). TP53 and MGMT status are shown below (WT, wild-type; D, null). p values represent significance (*p
% 0.05, **p % 0.01, ***p % 0.001, ****p % 0.0001). Arrows indicate the positions of the full-length proteins.

powerful gene-regulatory sequences, we show a method of creating
hypomorphic mutations that is titratable and predictable (Figures 1,
2, 3, and 4). We expanded use of poly(A) track insertions to create
hypomorphic mutants in integral membrane proteins (Figure 1). Integral membrane proteins make up 20%–30% of the proteome with
highly diverse functions. Integral membrane proteins constitute the
lipid bilayer of the membrane surrounding cellular organelles and
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the outside of the cell. They modulate movements of molecules and
information across membranes and serve essential functions as signal
receptors and transporters of solutes.51,52 Their importance for cell
function is apparent when these systems go awry; a substantial
amount of disease-linked mutations occur in integral membrane proteins. Therefore, these proteins make up over 50% of US Food and
Drug Administration (FDA)-approved drug targets.53
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As a result of their signiﬁcance in health and disease, we chose to
demonstrate the ability to create hypomorphic mutations in the transmembrane B cell antigen CD20 (Figure 1). By inserting 12A or 18A nucleotides directly following the second amino acid, we observed that
CD20 mRNA expression was reduced by 50% and 60%, respectively.
Protein expression was similarly reduced for both poly(A) track-containing reporters. In addition to successfully reducing CD20 expression
using this method, western blot analysis using a CD20 protein-speciﬁc
antibody indicated expression of the full-length CD20 at the expected
size of 33 kDa and the previously observed degradation product at
25 kDa.29 Furthermore, our live-cell imaging and ﬂow cytometry (Figure 2; Figure S1) indicated correct membrane localization and programmable reduction of membrane-inserted CD20 protein, supporting
our hypothesis that introducing additional adenosine nucleotides at the
N terminus of CD20 would not further affect localization and quality of
the protein.54 This result shows that N-terminal addition of the poly(A)
track in other membrane genes may successfully create hypomorphic
mutants.

poly(A) track allows a decrease in gene expression for all constructs,
the location may have a differential effect based on factors pertaining
to mRNA quality control mechanisms.58

Like membrane proteins, secretory proteins make up a large percentage of the proteome (11%) and serve diverse functions as hormones,
cytokines, and members of the extracellular matrix.36,55,56 Because of
these diverse functions, secretory proteins are essential for immune
responses and cell-to-cell communication. Furthermore, the recent
development of CAR-T cell therapies (Chimeric antigen receptor) indicates a need for attenuation of speciﬁc cytokines.57 By creating
hypomorphic mutations in alleles, these genes’ functions can be
examined or modulated, adding to the knowledge and signiﬁcance
of these genes in health and disease. With insertion of poly(A) tracks
in these secretory genes, we wanted to ensure that these additions or
mutations would not affect protein secretion by affecting the signal
peptide’s proteolytic cleavage. We used the cytokine IL-2 as a candidate because of the presence of a signal peptide at its N terminus
(Figure 3).

By combining our method with clustered regularly interspaced short
palindromic repeat (CRISPR)-Cas9-based methods, we can create
hypomorphic mutants endogenously. We tested this method by
creating endogenous AUF1 and TP53 hypomorphs in diploid
HEK293 cells and near-haploid human HAP1 cells, respectively (Figures 3 and 4). Introduction of 12As in the coding sequence of TP53
led to a decrease of 40% in mRNA stability and protein expression.
Endogenous insertion of 36As in the gene locus of the TP53 led to
an approximate 90% reduction in mRNA stability, and TP53 protein
expression was nearly undetectable by western blot (Figure 3). After inserting poly(A) tracks of 12As and 18As in the coding region of AUF1,
we saw reductions in the level of gene expression of approximately 40%
and 60%, respectively. Protein expression of the four major isoforms
(p37AUF1, p40 AUF1, p42AUF1, and p45AUF1) showed similar levels of
decrease in protein in expression (Figure 4). These results are consistent
with previously observed eukaryotic reporter gene poly(A) track insertions of 12As and 36As.19 The 40% knockdown in TP53 and AUF1 in
haploid and diploid cells, respectively, with insertion of 12As in each
gene supports the predictability and effectiveness of this tool for various
genes and cell types. By creating TP53 hypomorphs in the HAP1 line,
we examined the effects of poly(A) track insertion on TP53 expression
by mutating a single allele. The ability to create monoallelic hypomorphs using CRISPR-Cas9 and poly(A) tracks provides a feasible
and straightforward method for studying phenotypes when expression
of one allele is decreased.59 Moreover, TP53 hypomorphs can be used
to create a haploid state in haploid cells, such as HAP1, in which diploidization can occur.59,60 Our titratable method for hypomorph creation may be able to maintain the haploid state through a P53 reduction
without promoting the G1 cell cycle arrest and apoptosis that sometimes occur with deletion of P53.61

To test the effect of poly(A) track placement on IL-2 RNA stability
and secretion, we created gene reporters containing the complete coding sequence of IL-2 with poly(A) tracks of 9A, 12A, or 18A nucleotides inserted before or after the signal peptide (Figure 3A). Placement
of the poly(A) track in IL-2 did not affect IL-2 secretion, as shown by
the measurable amount and functionality of IL-2 protein in the supernatant of transfected HEK293 cells (Figures 3B and 3D). The mRNA
stability of IL2 and its protein expression were decreased for all constructs irrespective of the location of the poly(A) track insertion.
Furthermore, as shown in our previous studies, in which we created
hypomorphic reporter genes in eukaryotic cells, the decrease in IL2 gene expression is titratable, meaning gene knockdown depends
on the length of the poly(A) track.19 Although the magnitude of IL2 knockdown is greater in constructs with poly(A) tracks inserted after the signal peptide, this difference was not signiﬁcant (p < 0.05) and
was not clearly observed in a functional IL-2 assay (Figures 3B–3D).
However, one can imagine that this discrepancy in IL-2 expression
may result from the stalling and frameshifting mechanism of the
poly(A) track.16 Although the translational regulatory nature of the

When creating titratable CRISPR-Cas9-engineered endogenous hypomorphs, we examined application of this tool for understanding
the role of hypomorphic gene expression of AUF1 and TP53 in
expression of their downstream targets. After observing the differential effects of addition of 12As or 18As on downregulation of AUF1,
we assayed the effect of AUF1 protein reduction on previously
deﬁned targets, including MAT1A, APP, TOP2A, and USP1.25,62
Because AUF1 has been demonstrated to stabilize or destabilize
various targets, we expected that the reduction in AUF1 protein
would have differential effects on expression of target mRNAs, depending on their previously established relationships.63 For
example, siRNA-mediated silencing of AUF1 has been shown to stabilize expression of MAT1A.24 Our results support this relationship
between AUF1 and MAT1A. Reduced expression of AUF1 in 12A
and 18A hypomorphs lead to a moderate increase in MAT1A transcript expression slightly above WT levels (Figure 4D). Similarly,
photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) analysis identiﬁed post-transcriptional
gene regulation of APP, TOP2A, and USP1 by AUF1.25 AUF1 was
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found to interact with each mRNA through binding sites in the 30
UTR and, together with the HuR protein, regulates translational efﬁciency and stability of target mRNAs. Our results show that the
reduction in mRNA stability of each of these genes is related to
the level of AUF1 downregulation, with a stepwise decrease in
expression of these targets in 12A and 18A hypomorphs,
respectively.
We determined the differential expression of TP53 against several
cancer-related genes, including BRCA1, DUSP6, DDIT4, MGMT,
and P21 (Figure 6). Most notably, we observed that patterns of
decreased TP53 expression do not necessarily correlate with the
expression levels for downstream targets regulated by TP53. The differential effects of TP53 hypomorphs on DDIT4 and DUSP6 proteins
is more than intriguing, given that these proteins are connected with
TP53 status, the mammalian target of rapamycin (mTOR) pathway,
cell metabolism, and proliferation.45 There were also relatively stable
levels of BRCA1 expression in both cells containing 12A or 36A insertions, whereas MGMT and P21 were decreased by more than 85% in
both cell lines. Larger downregulation of MGMT and P21 than the
level of TP53 expression has been supported by previous
studies.49,59,64 Our study allows a more quantitative and tunable
approach to investigating the role of TP53 expression levels in modulation of downstream targets, accomplished previously with popular
methods such as RNAi.59 P21 levels under hydroxyurea treatment in
TP53 poly(A) track-engineered cells showed a delay in induction
compared with WT TP53 cells (Figure 6C).50 In the case of
MGMT, our tool’s precision and predictability may have utility for
uncovering a more cohesive role of TP53 downregulation on
MGMT expression and how this regulation affects chemoresistance
in certain cancers (Figure 6D).49
The utility of hypomorphic mutants created through poly(A) insertion can be seen in studies elucidating the function of proteins expressed in fungal pathogens such as Candida albicans. A recent study
in C. albicans showed a decrease in protein abundance with insertion
of poly(A) tracks of different lengths in the lanosterol demethylase
(Erg11p) and penta-functional AROM polypeptide (Aro1p), common
targets of antifungal agents.20 The reduction of both genes’ protein
expression using this method was predictable, with insertion of six
or more AAA codons causing a reduction in gene expression. Use
of hypomorphic mutants created through poly(A) tracks in the prevalent pathogen, C. albicans, supports this tool’s use in pathogenic microbes. With this tool, microbiologists can investigate the phenotypic
effects of genetic manipulation in host organisms without use of
xenobiotic agents and external environment changes. The results of
this study and previous studies showing the effects of poly(A) track
gene insertion undoubtedly support this tool’s utility. The tool has
been shown to be effective in eukaryotic and prokaryotic unicellular
and multicellular organisms utilizing reporter constructs and
CRISPR-Cas9. We predict that use of CRISPR-Cas9 for introduction
of poly(A) tracks and generation of titratable and straightforward
hypomorphic mutants will prove invaluable for synthetic biology
and genetic studies.
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MATERIALS AND METHODS
Cell culture

Hap1 TP53 cells were cultured in Iscove’s Modiﬁed Dulbecco’s Medium (IMDM) and supplemented with 10% Fetalgro and 5% penicillin
and streptomycin (Gibco) and L-glutamine (Gibco). Flp-In T-REx 293
cells AUF1 cell line was cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Gibco) and supplemented with 10% heat-inactivated
fetal bovine serum (Gibco), 5% minimum essential medium nonessential amino acids (100, Gibco), 5% penicillin and streptomycin
(Gibco), and L-glutamine (Gibco).
Additionally, 5 mg mL1 of blasticidin and 100 mg mL1 of Zeocin
were added to the medium for cell line maintenance. Flp-In T-REx
293 cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) (Gibco) and supplemented with 10% Fetalgro bovine
growth serum (BGS), 5% minimum essential medium nonessential
amino acids (100, Gibco), 5% penicillin, streptomycin (Gibco),
and L-glutamine (Gibco). Additionally, 5 mg mL1 of blasticidin
and 100 mg mL1 of Zeocin were added to the medium for cell
line maintenance. CHO-K cells were cultured in F-12K medium
(Kaighn’s modiﬁcation of Ham’s F-12 medium, Gibco) supplemented
with 10% Fetalgro BGS, 5% minimum essential medium nonessential
amino acids (100, Gibco), 5% penicillin and streptomycin (Gibco),
and L-glutamine (Gibco).

DNA constructs

IL-2 and CD20 constructs were created through PCR ampliﬁcation
from cDNA and genomic DNA, respectively. PCR products were puriﬁed using the Zymoclean Gel DNA Recovery Kit (Zymo Research)
and cloned into the pEntryD-Topo vector. From the pEntryD-Topo
vector, constructs were subcloned into the pcDNA-DEST40 or
pcDNA-DEST53 vector for expression using LR clonase recombination (LR Clonase II kit, Thermo Fisher Scientiﬁc). Constructs were
transformed using One Shot TOP10 chemically competent E. coli
cells (Thermo Fisher Scientiﬁc). Sequences for plasmid DNA were
conﬁrmed by Sanger sequencing (Genewiz).

CRISPR/Cas9-mediated gene editing

CRISPR-Cas9 genomic editing was performed by the Genome Engineering and IPSC Center (GEIC) at Washington University. Single
guide RNAs (sgRNAs) were designed according to sequences for
TP53 and AUF1, respectively, acquired from the Ensembl genetic
database. sgRNAs were selected based on off-target analysis performed by GEIC-speciﬁc algorithms. Ribonucleoproteins (RNPs)
containing recombinant CRISPR-Cas9 and sgRNA were transfected
to human cell lines using a Nucleofector (Lonza). Stable cell lines
were generated by selection of hygromycin resistance. After assessment of Cas9 NHEJ nuclease activity by the Cel-1 assay, cell lines
were propagated and assessed for positive insertion of poly(A) tracks
by qRT-PCR and sequencing analysis (Figures S1 and S2). A more
detailed description of these methods can be found in a publication
from GEIC.65
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Live imaging and flow cytometry of CD20-expressing cells

For live imaging, CHO-K cells were electroporated with a mCherry
reporter, WT CD20, or CD20 constructs containing an insertion of
12As and 18As, respectively, with the Neon Transfection System
(Thermo Fisher Scientiﬁc) using 100-mL tips and the cell line-speciﬁc
protocol (https://www.thermoﬁsher.com/us/en/home/life-science/
cell-culture/transfection/neon-transfection-system/neon-transfectionsystem-cell-line-data.html). 24 h after electroporation, cells were
washed twice with 1 PBS and blocked for 30 minutes with PBS/
BSA buffer (PBS [pH 7.4] and 1% BSA). After blocking, cells were
gently washed with 1 PBS before being incubated for 1 h in a
1:500 dilution of FITC-conjugated CD20 antibody (anti-human
CD20 FITC 2H7, Thermo Fisher Scientiﬁc) in PBS/BSA buffer.
Following incubation, cells were washed with 1 PBS prior to and after incubation for 1 h with a 1:8,000 dilution of Hoechst 33342 (Invitrogen) and 5 min with a 1:5,000 dilution of CellMask Orange plasma
membrane stain (Invitrogen) in 1 PBS. Cells were washed twice
with 1 PBS prior to imaging. Live ﬂuorescence imaging was performed at the Washington University Center for Cellular Imaging
(WUCCI). Cells were imaged using a Nikon A1Rsi scanning confocal
microscope in wide-ﬁeld mode and a Nikon CFI Plan Apochromat
20/0.75 objective. Emission was ﬁltered at 450 ± 50 nm (DAPI),
525 ± 25 nm (EGFP), and 595 ± 25 nm (mCherry/mTangerine). Cells
were maintained at 37 C with 5% CO2, controlled by a stagetop microscope incubation system (INU TIZW, TOKAI HIT, Japan).

1:8, and 1:16 dilutions using complete medium. Absorbance measurements were taken using the Synergy H4 hybrid multi-mode microplate reader (BioTek Instruments) at 450–550 nm. Concentrations
were interpolated from standard curves created with GraphPad Prism
statistical software.
IL-2 luciferase bioassay

According to the manufacturer’s protocol, cell supernatant from untransfected cells and cells transfected with IL-2 constructs was diluted
1:12 with complete medium and used to perform the IL-2 bioassay
(Promega, JA2201). Luminescence (RLU) was measured using the
GloMax Explorer multimode microplate reader. Average RLU values
were subtracted from background wells. Relative luciferase expression
was measured in reference to samples from cells transfected with WT
IL-2 constructs.
Hydroxyurea treatment

Hydroxyurea (Sigma-Aldrich) was kindly provided by Dr. Zhongsheng You. WT HAP1, HAP1 TP53 12A, and HAP1 TP53 18A cells
were transferred into 12-well plates 24 h before hydroxyurea treatment. Hydroxyurea was added to the medium to a ﬁnal concentration
of 1.5 mmol. Non-treated and hydroxyurea-treated cells were
collected 3 and 24 h after addition of hydroxyurea. Cell lysates were
used for western blot analysis.
Western blot analysis

For ﬂow cytometry experiments, CHO-K cells were seeded at a density
of 1.0  106 cells in a six-well plate 24 h before transfection. Cells were
cotransfected with mCherry reporters and WT CD20 or CD20 constructs containing an insertion of 12As or 18As, respectively. 48 h after
transfection, cells were trypsinized and pelleted. Cell pellets were
washed twice with 1 PBS before being blocked with PBS/BSA buffer
for 30 min on ice. After blocking, cell pellets were washed once with 1
PBS before 1-h incubation with a 1:500 dilution of FITC-conjugated
CD20 antibody. Cell suspensions were ﬁltered before FACS analysis using Partec North America CELLTRICS 100UM NS FLTR. Cytoﬂuorimetric analysis was performed to enumerate CD20-positive and
mCherry-positive CHO-K cells using the BD FACSCalibur system
(BD Biosciences).
ELISA

Flp-In T-REx 293 cells were plated at a density of 1.5  106 cells in
one well of six-well plates. Twenty-four hours after transfection
with WT IL-2 or IL-2 constructs containing inserted poly(A) tracks,
medium was collected. Medium was centrifuged at 1,500 rpm in a
centrifuge at 4 C for 10 min, and cell supernatant was collected.
The supernatant was used immediately or stored at 80 C. A
solid-phase sandwich ELISA (Thermo Fisher Scientiﬁc, EH2IL2)
was used to measure IL-2 concentration from cell supernatant according to the manufacturer’s protocol (https://assets.thermoﬁsher.
com/TFS-Assets/LSG/manuals/MAN0014639_EH2IL2_ELISA_Kit_
PI.pdf). Cell supernatant was diluted with complete cell medium at a
ratio of 1:10 to be within the concentration of a range of the standard
curve. Diluted cell supernatant was further diluted to obtain 1:2, 1:4,

Total cell lysates for western blot analysis of TP53, AUF1, and CD20
hypomorphs were prepared with passive lysis buffer (Promega) and
homogenized by passing ﬁve times through a 25G needle and syringe.
Total protein was measured from cell lysis using the Bio-Rad DC Protein Assay according to the manufacturer’s instructions (https://www.
bio-rad.com/webroot/web/pdf/lsr/literature/LIT448.pdf). CD20 samples were prepared in 1 Bio-Rad XT sample buffer with 5% b-mercaptoethanol with equal total protein concentrations. Samples were
boiled at 55 C for 10 min before loading on SDS-PAGE gel. AUF1
and TP53 samples were prepared in 1 Bio-Rad XT sample buffer
with a 1 XT reducing agent. Samples were boiled at 95 C for
5 min before loading on SDS-PAGE gel.
The CD20 blot was blocked overnight in 5% milk (w/v) in 1 PBS
with 0.1% Tween 20 (PBST). Blots were incubated in a 1:500 dilution
of CD20 primary antibody overnight (Thermo Fisher Scientiﬁc, PA516701) and a 1:5,000 dilution of anti-GFP (Takara, 632381). Blots
were washed (3  10 min) in TBST before and after incubation
with a 1:10,000 anti-mouse secondary antibody (Cell Signaling Technology, 7076S) overnight. The blots were washed overnight before being incubated with a 1:5,000 dilution of anti-actin-horseradish peroxidase (HRP) for 2 h at room temperature (Cell Signal, 13E5).
The TP53, BRCA1, DUSP6, DDIT4, and MGMT blots were blocked
overnight in 5% milk (w/v) in 1 PBST. All blots except for MGMT
(incubated for 1.5 h at room temperature) were incubated overnight
at 4 C in a 1:1,000 dilution with the following primary antibodies:
anti-TP53 (Cell Signal, 2524), anti-BRCA1 (Abclonal, A11034),
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anti-DUSP6 (Santa Cruz Biotechnology, 377070), anti-DDIT4 (Proteintech, 10638-1-AP), P21 (Cell Signal, 2947), and MGMT (Novus
Biologicals, NB-100-168). Blots were washed (3  10 min) in TBST
before and after incubation with a 1:10,000 anti-mouse secondary
antibody (Cell Signal, 7076S) or 1:10,000 anti-rabbit secondary
antibody (Cell Signal, 7074S) overnight. The blots were mildly stripped, washed vigorously, and blocked overnight in 5% milk (w/v) in
1 PBST before being incubated with a 1:5,000 dilution of anti-GAPDH-HRP (BioLegend, 649203) or a 1:2,000 dilution of anti-actin-HRP (5125).
The AUF1 blots were blocked overnight in 5% milk (w/v) in 1
PBST. The blots were incubated overnight at 4 C in a 1:2,000 dilution
of anti-AUF1 antibody (Cell Signal, D6O4F). The blots were washed
(3  10 min) in TBST before and after incubation with a 1:10,000
anti-rabbit secondary antibody (Cell Signal, 7074S). The blots were
washed overnight before being incubated with a 1:5,000 dilution of
anti-HSP70-HRP for 1 h at room temperature. All blots were washed
3  10 min in TBST before being developed with SuperSignal HRP
substrate (Thermo Fisher Scientiﬁc). Images for all blots were generated by the Bio-Rad Molecular Imager ChemiDoc XRS System with
Image Lab software.
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RNA isolation and cDNA synthesis

Total RNA was extracted from Flp-In T-REx 293, CHO-K, and HAP1
cell pellets using the Illustra TriplePrep Kit (GE Healthcare Life Sciences) according to the manufacturer’s instructions. An optional oncolumn DNase treatment was performed to remove genomic DNA
(https://cdn.cytivalifesciences.com/dmm3bwsv3/AssetStream.aspx?
mediaformatid=10061&destinationid=10016&assetid=13444). RNA
concentration was measured by NanoDrop (optical density 260
[OD260]/OD280). One mg of total RNA was used to synthesize
cDNA using SuperScript IV VILO Master Mix (Thermo Fisher
Scientiﬁc).
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